Friday, July 10, 2026

Drug profile · INN

lurasidone

lurasidone (APO-LURASIDONE) is a dopamine d2 receptor antagonist. Associated with Alphapharm Pty Ltd.

EMA: approved TGA: approved Nervous system (N05) N05AE05
Patents linked 1
Pipeline programs 3
News articles 0
Drug details — lurasidone
Class
Nervous system (N05)
Route
Patents
1
Programs
3
Data quality
0.83

Quick answer

lurasidone (APO-LURASIDONE) is a dopamine d2 receptor antagonist. Associated with Alphapharm Pty Ltd.

Key facts

INN lurasidone
Brand APO-LURASIDONE
Mechanism Dopamine D2 receptor antagonist
Therapeutic class Nervous system (N05)
ATC code N05AE05

Mechanism of action

Dopamine D2 receptor antagonist

Approval history

Authority Status Date
EMA approved
TGA approved

Pipeline programs

  1. Lurasidone Phase 3 · Sumitomo Pharma Co · Bipolar I Depression
  2. INTENSIFY SZ Approved · Disc Medicine · schizophrenia, schizoaffective disorder, schizophrenifom dis
  3. NL6220204217 Approved · Disc Medicine · HAMLETT compares regular treatment guidelines for patients i

Related & competitor drugs

  1. aripiprazole Nervous system (N05)
  2. brexpiprazole Nervous system (N05)
  3. brivaracetam Nervous system (N03)
  4. bupivacaine Nervous system (N01)
  5. buprenorphine Nervous system (N07)
  6. caffeine citrate Nervous system (N06)
  1. US 11090272

    Lurasidone solid dispersion and preparation method thereof

    Expires Mon Aug 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is lurasidone?

lurasidone (APO-LURASIDONE) is a dopamine d2 receptor antagonist. Associated with Alphapharm Pty Ltd.

What is the brand name for lurasidone?

APO-LURASIDONE is a marketed brand name for lurasidone. Check FDA Drugs@FDA for the current US label holder and prescribing information.